Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia
Top Cited Papers
Open Access
- 18 June 2021
- Vol. 9 (6), 674
- https://doi.org/10.3390/vaccines9060674
Abstract
Background: Pfizer-BioNTech and Oxford-AstraZeneca are recently introduced vaccines to combat COVID-19 pandemic. During clinical trials, mild to moderate side effects have been associated with these vaccines. Thus, we aimed to evaluate short-term post-vaccination side effects. Methods: Cross-sectional, retrospective study using an online questionnaire was conducted among COVID-19 vaccines recipients in Saudi Arabia. General and demographic data were collected, and vaccine-associated side effects after receiving at least one dose of each vaccine were evaluated. Results: Our final sample consisted of 515 participants with a median age of 26 years. Most of the study participants were female (57%). Nearly 13% of the study subjects have reported previous infections with SARS-CoV-2. Oxford-AstraZeneca and Pfizer-BioNTech vaccines have been received by 75% and 25% of the study participants, respectively. Side effects associated with COVID-19 vaccines have been reported by 60% of the study subjects, and most of them reported fatigue (90%), pain at the site of the injections (85%). Conclusion: Side effects that are reported post Oxford-AstraZeneca and Pfizer-BioNTech vaccines among our study participants are not different from those that were reported in the clinical trials, indicating safe profiles for both vaccines. Further studies are needed to evaluate the effectiveness of the current vaccines in protection against SARS-CoV-2 reinfections.This publication has 21 references indexed in Scilit:
- Ethical and Scientific Considerations Regarding the Early Approval and Deployment of a COVID-19 VaccineAnnals of Internal Medicine, 2021
- COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine developmentJournal of Biosciences, 2020
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialThe Lancet, 2020
- Understanding COVID-19 vaccine efficacyScience, 2020
- Severe acute respiratory syndrome‐coronavirus‐2 spike (S) protein based vaccine candidates: State of the art and future prospectsReviews in Medical Virology, 2020
- A brief review of socio-economic and environmental impact of Covid-19Air Quality, Atmosphere & Health, 2020
- Preparedness and response to COVID-19 in Saudi Arabia: Building on MERS experienceJournal of Infection and Public Health, 2020
- WHO Declares COVID-19 a Pandemic2020
- Vaccine hesitancyHuman Vaccines & Immunotherapeutics, 2013
- Addressing the vaccine confidence gapThe Lancet, 2011